ImmuneRegen BioSciences, Inc. Announces First Study Of Viprovex(TM) To Explore Adjuvant Capabilities In The Area Of Pandemic Influenza Vaccine

... ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced it has commenced the first study of Viprovex(TM) to explore its adjuvant capabilities in the area of Pandemic Influenza Vaccine. The study is being conducted in conjunction with privately-held vaccine developer GenPhar, Inc., of Charleston, SC. [click link for full article] ...